InterMune Research Coverage Started at Cowen and Company (ITMN)
Investment analysts at Cowen and Company assumed coverage on shares of InterMune (NASDAQ:ITMN) in a note issued to investors on Thursday, TheFlyOnTheWall.com reports. The firm set a “market perform” rating and a $74.00 price target on the stock. Cowen and Company’s price target points to a potential upside of 1.12% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at JMP Securities downgraded shares of InterMune from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Separately, analysts at JPMorgan Chase & Co. downgraded shares of InterMune from an “overweight” rating to a “neutral” rating in a research note on Tuesday. They now have a $74.00 price target on the stock. Finally, analysts at Jefferies Group upgraded shares of InterMune from an “underperform” rating to a “hold” rating in a research note on Monday. They now have a $74.00 price target on the stock, up previously from $25.00. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. InterMune presently has a consensus rating of “Hold” and a consensus price target of $59.25.
Shares of InterMune (NASDAQ:ITMN) opened at 73.18 on Thursday. InterMune has a 52 week low of $10.95 and a 52 week high of $73.25. The stock has a 50-day moving average of $48.36 and a 200-day moving average of $37.63. The company’s market cap is $7.901 billion. InterMune also saw some unusual options trading on Monday. Investors acquired 5,253 call options on the company. This is an increase of 156% compared to the typical daily volume of 2,052 call options.
InterMune (NASDAQ:ITMN) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.72) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter last year, the company posted ($0.77) earnings per share. InterMune’s revenue was up 141.2% compared to the same quarter last year. Analysts expect that InterMune will post $-2.75 EPS for the current fiscal year.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.